BioSpace News Archive

USANA Health Sciences, Inc. (NYSE:USNA) today announced that fourth quarter results will be released after the close of market Tuesday, February 9, 2021. Shortly following the issuance of the Company’s earnings release, the Company will post a “Management Commentary, Results and Outlook” document on the Company’s website ( http://ir.usana.com ) under the “Investor Relations” section of the site. The following morning at 11

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced that the journal Nature Methods has selected spatially-resolved transcriptomics as their prestigious Method of the Year for 2020.

Willamette Surgery Center achieved a milestone in 2020, performing 200 total joint replacements as of November and finished the year with a record 254 total joint replacements.

SOLVD Health (www.solvdhealth.com), a privately held company focused on preventing disease by making actionable and contextual health information accessible to everyone, is preparing to launch a U.S. clinical study of its non-invasive colorectal cancer (CRC) screening test, LifeKit® Prevent.

Genesis Biotechnology Group® (GBG) and its Contract Research Organization (CRO) arm Genesis Drug Discovery & Development™ (GD3) announced today that it has acquired the Cincinnati-based CRO STATKING Clinical Services.

ValGenesis, Inc., a market leader in Enterprise Validation Lifecycle Management Systems (VLMS), today announced that a pioneering gene therapy company has selected ValGenesis VLMS – the industry’s most trusted electronic validation lifecycle management system, to digitize its corporate validation process

Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that it has initiated the submission of a New Drug Application (NDA) to the Health Sciences Authority (HSA) of Singapore for sacituzumab govitecan-hziy

Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People’s Republic of China has approved a Clinical Trial Application (CTA) for sacituzumab govitecan-hziy

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that members of its executive leadership team will virtually present at the 39th Annual J.P. Morgan Healthcare Conference at 8:20 a.m. ET on January 11, 2021. A live webcast of the presentation

American BriVision Corporation, a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system, and ophthalmology, yesterday issued a letter to its more than 700 shareholders describing the company’s achievements in 2020 and goals for 2021.